Dutch Startup Phosphoenix Develops Vision-Restoring Brain Implant
Netherlands, Friday, 9 May 2025.
Phosphoenix is creating a brain implant to restore vision using electrical stimulation, aiming to help those who are blind. Support from Dutch authorities is crucial in this groundbreaking endeavor.
Revolutionary Approach to Vision Restoration
Founded in 2019 by Prof. Pieter Roelfsema, Dr. Bert Monna, and Prof. Xing Chen [2], Phosphoenix’s innovative technology bypasses the eyes entirely, focusing instead on direct brain stimulation. The system works by introducing 1,000 electrodes through a small opening in the skull, enabling the generation of light points sufficient for basic spatial orientation [1]. This groundbreaking approach allows users to identify fundamental objects like tables and doorways, providing essential navigational capabilities for daily life [1].
Recent Funding Milestones
The Amsterdam-based startup has secured significant financial backing in 2025, including a €2.5 million EIC Transition grant in January for their SIGHTED project [2]. Most recently, on April 30, 2025, Innovatiefonds Noord-Holland (INH) announced their investment in the company [2]. Fund manager Ludolf Stavenga highlighted the unique potential of Phosphoenix’s neurotech solution for vision restoration [2].
Technical Innovation and Long-term Vision
The technology represents a significant advancement in medical device development, designed to function within the human body for 20 to 30 years [1]. According to Hans Brons, CEO of Phosphoenix, this financing marks a crucial step toward making their innovative medical solution globally accessible [2]. The system utilizes a camera connected to the brain, converting visual input into electrical signals that create perception through electrode stimulation [2].
Development Timeline and Support
The project receives crucial support from the Rijksdienst voor Ondernemend Nederland (RVO), which provides various funding mechanisms including WBSO and assistance with European financing programs such as Eurostars, ERC, and EIC of Horizon Europe [1]. The company is currently in the pre-clinical validation phase and preparing for clinical studies [2]. This extensive development process reflects the rigorous requirements for medical device commercialization, particularly for innovations involving brain implantation [1].